XML 30 R15.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Financial risk management | 6 Months Ended
--- | ---
Dec. 31, 2023
Disclosure Of Financial Risk Management [Abstract] |
Financial risk management | Financial risk management This note explains the Group’s exposure to financial risks and how these risks could affect the Group’s future financial performance. Current year profit and loss information has been included where relevant to add further context.
Risk |  | Exposure arising from |  | Measurement |  | Management
Market risk – currency risk |  | Future commercial transactions Recognized financial assets and liabilities not denominated in the functional currency of each entity within the Group |  | Cash flow forecasting Sensitivity analysis |  | The future cash flows of each currency are forecast and the quantum of cash reserves held for each currency are managed in line with future forecasted requirements. Cross currency swaps are undertaken as required.
Market risk – interest rate risk |  | Term deposits at fixed rates Cash deposits at variable rates |  | Sensitivity analysis |  | Vary length of term deposits, utilize interest bearing accounts and periodically review interest rates available to ensure we earn interest at market rates.
Market risk – price risk |  | Long-term borrowings |  | Sensitivity analysis |  | Forecasts of net sales of the product underlying the NovaQuest borrowing arrangement are updated on a quarterly basis to evaluate the impact on the carrying amount of the financial liability.
Market risk – share price risk |  | Warrant liability |  | Sensitivity analysis |  | The future exercise of warrants will not impact the Group's future cash flows significantly given the warrants will be paid in shares upon exercise. Therefore there are no significant cashflow risks associated with these warrants. The Group monitors the impact on profit or loss that share price movements have on the valuation of the warrant liability each period.
Credit risk |  | Cash and cash equivalents, and trade and other receivables and other non-current assets |  | Aging analysis Credit ratings |  | Transact primarily with the best risk rated banks available in each region giving consideration to the products required, the quantum of cash reserves held and future forecasted requirements.
Liquidity risk |  | Cash and cash equivalents, borrowings, trade payables, lease liabilities and contingent consideration |  | Rolling cash flow forecasts |  | Future cash flow requirements are forecasted and capital raising strategies are planned to ensure sufficient cash balances are maintained to meet the Group’s future commitments.
a. Market risk (i) Currency risk The Group has foreign currency amounts owing relating to clinical, regulatory and overhead activities and foreign currency deposits held primarily in the Group’s Australian based entity, whose functional currency is the A$. The Group also has foreign currency amounts owing in the Group’s Swiss and Singapore based entities, whose functional currencies are the US$. The Group also has foreign currency amounts owing in various other non-US$ currencies in A$ and US$ functional currency entities in the Group relating to clinical, regulatory and overhead activities. These foreign currency balances give rise to a currency risk, which is the risk of the exchange rate moving, in either direction, and the impact it may have on the Group’s financial performance. Currency risk is minimized by ensuring the proportion of cash reserves held in each currency matches the expected rate of spend of each currency. As of December 31, 2023, the Group held 68% of its cash in US$, 31% in A$ and 1% in other currencies. As of June 30, 2023, the Group held 67% of its cash in US$, and 33% in A$. (ii) Cash flow and fair value interest rate risk The Group is exposed to interest rate movements which impacts interest income earned on its deposits and at call accounts. The interest rate risk is managed by spreading the maturity date of our deposits across various periods. The Group ensures that sufficient funds are available, in at call accounts, to meet the working capital requirements of the Group. The deposits held which derive interest revenue are described in the table below, together with the maximum and minimum interest rates being earned as of December 31, 2023 and June 30, 2023. The effect on profit is shown if interest rates change by 10%, in either direction, is as follows:
| As of December 31, 2023 |  | As of June 30, 2023
(in U.S. dollars, in thousands, except percent data) | Low |  | High |  | US$ |  | Low |  | High |  | US$
Funds invested - US$ | 1.84 | % |  | 1.84 | % |  | 49,950 |  |  | 1.79 | % |  | 1.79 | % |  | 40,569 |
Rate increase by 10% | 2.02 | % |  | 2.02 | % |  | 92 |  |  | 1.97 | % |  | 1.97 | % |  | 73 |
Rate decrease by 10% | 1.66 | % |  | 1.66 | % |  | (92) |  |  | 1.61 | % |  | 1.61 | % |  | (73) |
| As of December 31, 2023 |  | As of June 30, 2023(1)
(in Australian dollars, in thousands, except percent data) | Low |  | High |  | A$ |  | Low |  | High |  | A$
Funds invested - A$ | 3.85 | % |  | 4.88 | % |  | 35,466 |  |  | 3.60 | % |  | 4.59 | % |  | 35,707 |
Rate increase by 10% | 4.24 | % |  | 5.37 | % |  | 151 |  |  | 3.96 | % |  | 5.05 | % |  | 143 |
Rate decrease by 10% | 3.47 | % |  | 4.39 | % |  | (151) |  |  | 3.24 | % |  | 4.13 | % |  | (143) |
(1) A$ deposits held as of June 30, 2023 have been updated to reflect the increasing impact of higher interest rates. (iii) Price risk Price risk is the risk that future cash flows derived from financial instruments will be altered as a result of a market price movement, which is defined as movements other than foreign currency rates and interest rates. The Group is exposed to price risk which arises from long-term borrowings under its facility with NovaQuest, where the timing and amounts of principal and interest payments is dependent on net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in the United States and other territories excluding Asia. As net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in these territories increase/decrease, the timing and amount of principal and interest payments relating to this type of financing arrangement will also fluctuate, resulting in an adjustment to the carrying amount of the financial liability. The adjustment is recognized in the Consolidated Income Statement as remeasurement of borrowing arrangements within finance costs in the period the revision is made. The exposure of the Group’s borrowing to price rate changes are as follows:
| As of December 31, 2023 |  | As of June 30, 2023
(in U.S. dollars, in thousands, except percent data) | Total |  | % of total borrowings |  | Total |  | % of total borrowings
Financial liabilities |  |  |  |  |  |  |
Current borrowings |  |  |  |  |  |  |
Borrowings - NovaQuest | 367 |  |  | 0 | % |  | 336 |  |  | 0 | %
Non-current borrowings |  |  |  |  |  |  |
Borrowings - NovaQuest | 60,878 |  |  | 53 | % |  | 55,739 |  |  | 51 | %
| 61,245 |  |  | 53 | % |  | 56,075 |  |  | 51 | %
As at December 31, 2023, all other factors held constant, a +/- 20% increase/decrease in the forecast net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in the United States and other territories excluding Asia would not have a significant impact on non-current borrowing and profit. The Group is also exposed to price risk on contingent consideration provision balances, as expected unit revenues are a significant unobservable input used in the level 3 fair value measurements. As at December 31, 2023, all other factors held constant, the increase/decrease in price assumptions adopted in the fair value measurements of the contingent consideration provision are discussed in Note 5(e)(iv). The Group does not consider it has any exposure to price risk other than those already described above. (iv) Share price risk The Group's exposure to share price risk arises from warrant liabilities held by the Group and classified in the statement of financial position at fair value through profit or loss. The future exercise of these warrants will not impact the Group's future cash flows significantly given the warrants will be paid in shares upon exercise, therefore there are no significant cashflow risks associated with these warrants. The Group monitors the impact on profit or loss that share price movements have on the valuation of the warrant liability each period. The table below summarizes the impact of the increase/decrease of Mesoblast's share price on the Group's profit or loss during the period, based on the assumption that the share price had increased/decreased by 10% and 10% with all other variables held constant as of December 31, 2023 and June 30, 2023 respectively.
(in U.S. dollars, in thousands) | As of December 31, 2023 |  | As of June 30, 2023
Financial liabilities |  |  |  |
Warrant liability |  | 992 |  |  | 5,426 |
Impact on profit or (loss) |  |  |  |
Share price increase by 10% (2023: 10%) |  | (144) |  |  | (698) |
Share price decrease by 10% (2023: 10%) |  | 140 |  |  | 686 |
b. Credit risk Credit risk is the risk that one party to a financial instrument will fail to discharge its obligation and cause financial loss to the other party. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets as mentioned in Note 5. c. Liquidity risk Liquidity risk is the risk that the Group will not be able to pay its debts as and when they fall due. Liquidity risk has been assessed in Note 1(i). All financial liabilities, excluding contingent consideration, borrowings and lease liabilities held by the Group as of December 31, 2023 and June 30, 2023 mature within 6 months. Trade payables and contingent consideration held by the Group as of December 31, 2023 and June 30, 2023 are non-interest bearing. The total contractual cash flows associated with trade payables equate to the carrying amount disclosed within the financial statements. As of December 31, 2023, the maturity profile of the anticipated future contractual cash flows on an undiscounted basis and removing probability adjustments as applicable for contingent consideration, and which therefore differs from the carrying value, is as follows:
(in U.S. dollars, in thousands) | Within 1 year |  | Between 1-2 years |  | Between 2-5 years |  | Over 5 years |  | Total contractual cash flows |  | Carrying amount
Borrowings(1)(2) | (9,739) |  |  | (18,242) |  |  | (143,701) |  |  | — |  |  | (171,682) |  |  | (115,763) |
Trade payables | (10,760) |  |  | — |  |  | — |  |  | — |  |  | (10,760) |  |  | (10,760) |
Lease liabilities | (3,131) |  |  | (2,877) |  |  | (613) |  |  | — |  |  | (6,621) |  |  | (6,237) |
Contingent consideration(3) | (5,000) |  |  | (881) |  |  | (141) |  |  | — |  |  | (6,022) |  |  | (612) |
| (28,630) |  |  | (22,000) |  |  | (144,455) |  |  | — |  |  | (195,085) |  |  | (133,372) |
(1)Contractual cash flows include payments of principal, interest and other charges. Interest is calculated based on debt held at December 31, 2023 without taking into account drawdowns of further tranches. (2)In relation to the contractual maturities of the NovaQuest borrowings, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of pediatric SR-aGVHD in the United States and other territories excluding Asia. (3)In relation to the contractual maturities of the royalty payments related to contingent consideration, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of children and adults with aGVHD. Product royalties will be payable in cash which will be funded from royalties received from net sales. With respect to future milestone payments, contingent consideration will be payable in cash or shares at our discretion. The carrying amount reflects the discounted and probability adjusted contractual balance related to royalty payments. Purchase commitments In December 2019, the Group commenced production under its manufacturing service agreement with Lonza for the supply of commercial product for the potential approval and launch of remestemcel-L for the treatment of pediatric SR-aGVHD in the US market. This agreement contains lease and non-lease components. As of December 31, 2023, the agreement contains a minimum remaining financial commitment of the non-lease component of $12.7 million, payable until June 2025, which is cancellable in limited circumstances. The Group has accounted for the lease component within the agreement as a lease liability separately from the non-lease components. As of December 31, 2023, the lease component is $2.5 million on an undiscounted basis, as disclosed within the total contractual cash flows as lease liabilities in Note 9(c). At the Group's discretion, the minimum financial commitment under this manufacturing services agreement can be reduced by $7.4 million under certain conditions, with $1.5 million of this reduction relating to the lease component and $5.9 million relating to the non-lease component of the agreement. The Group have agreements with third parties related to contract manufacturing and other goods and services. As of December 31, 2023, the Group had $5.7 million of non-cancellable purchase commitments related to raw materials, manufacturing agreements and other goods and services (excluding those with Lonza). This amount represents our minimum contractual obligations, including termination fees. Certain agreements provide for termination rights subject to termination fees. Under such agreements, the Group are contractually obligated to make certain payments, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. The Group did not have any other purchase commitments as of December 31, 2023.

X
- Definition The disclosure of the entity's financial risk management practices and policies. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfFinancialRiskManagementExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of financial risk management. + References No definition available. + Details
Name: | meso_DisclosureOfFinancialRiskManagementAbstract
Namespace Prefix: | meso_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration